PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.
Victoria K WoodcockJi-Li ChenKarin PurshouseChrissie ButcherLinda CollinsCaroline HaddonGillian VerrallLeena ElhusseinCorran RobertsAndrea TarltonMargarida ReiGiorgio NapolitaniMariolina SalioMark R MiddletonVincenzo CerundoloJeremy CrewAndrew S ProtheroePublished in: BJUI compass (2023)
Administration of intravesical pembrolizumab was well tolerated and did not raise any safety concerns in patients with NMIBC following TURBT. There was no evidence of systemic absorption or systemic immune effects following intravesical administration. Further studies are required to assess whether intravesical administration has anti-tumour activity.